CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		9 Months Ended
		Oct. 02, 2016		Sep. 27, 2015
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3]	$ 6,380		$ 7,155
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[2]	4,208		3,733
Asset write-offs and impairments	[2]	1,146		864
Write-down of HIS net assets to fair value less estimated costs to sell	[2],[4]	1,422		0
Deferred taxes from continuing operations	[2]	(1,335)		(165)
Share-based compensation expense	[2]	532		488
Benefit plan contributions in excess of expense	[2]	(775)		(804)
Other adjustments, net	[2]	68		(184)
Other changes in assets and liabilities, net of acquisitions and divestitures	[2]	(1,718)		(1,297)
Net cash provided by operating activities	[2]	9,929		9,790
Investing Activities
Purchases of property, plant and equipment	[2]	(1,134)		(786)
Purchases of short-term investments	[2]	(15,170)		(21,068)
Proceeds from redemptions/sales of short-term investments	[2]	20,685		33,609
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[2]	6,485		5,557
Purchases of long-term investments	[2]	(4,771)		(6,578)
Proceeds from redemptions/sales of long-term investments	[2]	6,915		4,535
Acquisitions of businesses, net of cash acquired	[2]	(17,679)		(16,322)
Acquisitions of intangible assets	[2]	(96)		(48)
Other investing activities, net	[2]	60		346
Net cash used in investing activities	[2]	(4,704)		(756)
Financing Activities
Proceeds from short-term borrowings	[2]	6,397		2,022
Principal payments on short-term borrowings	[2]	(3,321)		(16)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[2]	(963)		1,907
Proceeds from issuance of long-term debt	[2]	5,031		0
Principal payments on long-term debt	[2]	(4,317)		(2,994)
Purchases of common stock	[2]	(5,000)		(6,160)
Cash dividends paid	[2]	(5,496)		(5,211)
Proceeds from exercise of stock options	[2]	946		1,165
Other financing activities, net	[2]	29		171
Net cash used in financing activities	[2]	(6,693)		(9,115)
Effect of exchange-rate changes on cash and cash equivalents	[2]	(79)		(162)
Net decrease in cash and cash equivalents	[2]	(1,547)		(244)
Cash and cash equivalents, beginning	[2]	3,641	[5]	3,343
Cash and cash equivalents, end	[2]	2,094	[5]	3,099
Cash paid during the period for:
Income taxes	[2]	1,430		1,414
Interest	[2]	$ 1,177		$ 1,162

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] Amounts may not add due to rounding.

[4] In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information.

[5] Amounts may not add due to rounding.